Company Overview and News

212
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug

15h zacks
Shares of Solid Biosciences Inc. (SLDB - Free Report) surged 10.9% after the company announced that the FDA has lifted the clinical hold on its phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001.
NEE.PRI NEE.PRJ SLDB NEE.PRC OXB NEE.PRQ NEE.PRR OXBDF NEE AXON

212
Axovant's Parkinson's Gene Therapy Is Extremely Risky

22h seekingalpha
Axovant purchased an experimental Parkinson's gene therapy and is expected to start a clinical trial later this year.
ARNA OXB OXBDF AXON

217
Gene Therapy Prospects Make Axovant Sciences A Compelling Buy For 2018

2018-06-15 seekingalpha
Axovant Sciences' (AXON) licensing deal with Oxford BioMedica (OTCPK:OXBDF) is nothing short of a masterstroke. This deal has opened up the gene therapy segment for Axovant Sciences and has positioned the company to make a solid entry in the neurodegenerative disease segment. This transformation from being a small molecule player to a very potent lentiviral vector gene therapy company initially targeting Parkinson's disease or PD has been well received by the investor community.
OXB NVS OXBDF SNY AXON

370
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

2018-06-13 zacks
The biotech sector was in focus last week with regular pipeline updates and collaboration/licensing deals. While biotech bigwig Amgen’s (AMGN - Free Report) drugs won both FDA and EC approvals, Axovant (AXON - Free Report) soared on a licensing deal Oxford BioMedica. Meanwhile, Regeneron (REGN - Free Report) collaborated with Zoetis to discover new veterinary treatments.
AMGN ALXN BIIB OXB OXBDF AXON

216
Axovant Sciences: Expect A Crash After An Overhyped Deal With Oxford BioMedica

2018-06-12 seekingalpha
Axovant Sciences skyrocketed after a licensing agreement with Oxford BioMedica and investment by Roivant, resulting in a $373 million increase to its valuation.
IMDZ OXB LNSTY OXBDF AXON

279
What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month | InvestorPlace

2018-06-11 investorplace
As a micro-cap company, Axovant Sciences Ltd (NASDAQ:AXON) is naturally fraught with risks. The company is losing money and debt levels are elevated at 0.49 times equity. But with the stock trading at around five times book value, what expectations should investors have for this biotechnology company from the United Kingdom?
AGN AGN.PRA OXB ACT OXBDF AXON

215
Rounds Report: Axovant Rallied, FDA Due Diligence To Serve As Industry Tailwind For Therapeutic Innovators

2018-06-08 seekingalpha
Riding on the strength of the previous session, the bioscience market rallied aggressively. Many equities under our coverage procured substantial gains for investors.
OXB IBB XBI OXBDF ONCE AXON

217
Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session

2018-06-08 zacks
Axovant Sciences Ltd. (AXON - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $1.14 to $4.55 in the past one month time frame.
UNP OXB OXBDF GHDX AXON

17
Axovant Makes A Bold Move In Licensing Gene Therapy Treatment, Will It Change Its Future?

2018-06-08 seekingalpha
Axovant announces global licensing deal with Oxford BioMedica for a gene therapy product known as OXB-102 (now known as AXO-LentiPD).
BLUE OXB GSK BLUE GSK OXBDF ONCE

117
Facebook Procures Content from News Organizations for Watch

2018-06-07 zacks
Facebook (FB - Free Report) , reportedly, will pay and share advertising revenues for content produced by news organizations like Time Warner’s (TWX - Free Report) CNN, Fox News and Univision. Per Reuters, the social media giant plans to launch U.S. news programs for its video service, Watch, in 2018. The original content from these news providers is expected to solve the fake news menace on Facebook’s platform.
COF.PRG COF.PRH FB COF-P TWX COF.WS COF.PRP COF TWC OXBDF COF-D COF-C COF-F GOOGL TWTR OXB COF.PRC OXY COF.PRD DIS COF.PRF

110
Northrop Grumman Completes Orbital ATK Takeover for $9.2B

2018-06-07 zacks
Northrop Grumman Corporation (NOC - Free Report) recently announced the completion of its Orbital ATK acquisition for a total value of $9.2 billion. Interestingly, the news surfaced a day post the U.S. Federal Trade Commission (FTC) gave the final go-ahead to the deal’s closure, subject to a few conditions. In line with the FTC’s announcement, post acquisition, Orbital ATK has become Northrop Grumman’s fourth business unit under the name of Innovation Systems.
COF.PRG COF.PRH WAIR COF-P COF.WS COF.PRP COF AVAV OXBDF OA COF-D COF-C NOC COF-F BOE OXB BA COF.PRC OXY COF.PRD COF.PRF

57
Why Should You Retain Republic Services in Your Portfolio?

2018-06-07 zacks
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions.
COF.PRG COF.PRH COF-P COF.WS COF.PRP COF OXBDF COF-D COF-C COF-F PAY RSG OXB WEX COF.PRC OXY COF.PRD FLT COF.PRF

265
Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica

2018-06-07 zacks
Shares of Axovant Sciences (AXON - Free Report) gained 160%, after the company announced that it has licensed the exclusive worldwide rights to develop and commercialize AXO-LentiPD from Oxford BioMedica for Parkinsons’ disease.
COF.PRG COF.PRH COF-P COF.WS COF.PRP COF OXBDF ONCE COF-D COF-C COF-F OXB NVS COF.PRC OXY COF.PRD FGP AXON COF.PRF

305
AXON / Axovant Sciences Ltd. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-07 fintel.io
Axovant Sciences Ltd. (NASDAQ:AXON) has 95 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 21,934,482 shares. Largest shareholders include Janus Capital Management Llc, BlackRock Inc., Renaissance Technologies LLC, Millennium Management Llc, IPL Advisers, LLC, Primecap Management Co/ca/, Deutsche Bank Ag\, BlackRock Fund Advisors, Hudson Bay Capital Management LP, and Two Sigma Investments Llc.
BLK DB VBLT OXB VBLTF ALDR OXBDF AXON

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to LSE:OXB / OXFORD BIOMEDICA PLC on message board site Silicon Investor.

Oxford Biomedica, (OXB). VXBX - Voxbox (Bulls Board)
Oxbow Exploration Inc.